Anthony Petrone
Stock Analyst at Mizuho
(3.96)
# 396
Out of 4,829 analysts
168
Total ratings
52.03%
Success rate
8.78%
Average return
Main Sectors:
Stocks Rated by Anthony Petrone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GKOS Glaukos | Maintains: Outperform | $200 → $175 | $94.64 | +84.91% | 8 | Apr 16, 2025 | |
| EMBC Embecta | Initiates: Neutral | $15 | $12.41 | +20.87% | 1 | Apr 10, 2025 | |
| GH Guardant Health | Initiates: Outperform | $55 | $41.66 | +32.02% | 1 | Apr 10, 2025 | |
| SENS Senseonics Holdings | Initiates: Outperform | $2 | $0.60 | +233.33% | 1 | Apr 10, 2025 | |
| TNDM Tandem Diabetes Care | Initiates: Neutral | $20 | $23.45 | -14.71% | 1 | Apr 10, 2025 | |
| DXCM DexCom | Initiates: Outperform | $85 | $85.05 | -0.06% | 1 | Apr 10, 2025 | |
| EXAS Exact Sciences | Initiates: Outperform | $60 | $53.40 | +12.36% | 1 | Apr 10, 2025 | |
| ALC Alcon | Maintains: Outperform | $115 → $120 | $94.79 | +26.60% | 9 | Mar 28, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $54 → $58 | $44.20 | +31.22% | 2 | Mar 6, 2025 | |
| LIVN LivaNova | Maintains: Outperform | $70 → $60 | $45.23 | +32.66% | 8 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $87 | $58.81 | +47.93% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $275 → $250 | $129.24 | +93.44% | 7 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $110 | $102.87 | +6.93% | 8 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $115 → $130 | $131.99 | -1.51% | 4 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $14 | $20.45 | -31.54% | 6 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $70 | $34.58 | +102.43% | 6 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $53 → $55 | $20.27 | +171.34% | 7 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $100 | $79.52 | +25.75% | 5 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $105 | $74.11 | +41.68% | 6 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $105 | $74.80 | +40.37% | 7 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $215 | $247.66 | -13.19% | 15 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $250 | $156.44 | +59.81% | 6 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $7.25 | +93.10% | 4 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $103 → $115 | $84.45 | +36.18% | 14 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $98 | $85.81 | +14.21% | 4 | Feb 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $350 → $390 | $561.43 | -30.53% | 6 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $63 → $67 | $82.46 | -18.75% | 2 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $115 | $70.26 | +63.68% | 14 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $175 | $98.22 | +78.17% | 3 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $30 → $25 | $7.52 | +232.45% | 3 | May 13, 2020 |
Glaukos
Apr 16, 2025
Maintains: Outperform
Price Target: $200 → $175
Current: $94.64
Upside: +84.91%
Embecta
Apr 10, 2025
Initiates: Neutral
Price Target: $15
Current: $12.41
Upside: +20.87%
Guardant Health
Apr 10, 2025
Initiates: Outperform
Price Target: $55
Current: $41.66
Upside: +32.02%
Senseonics Holdings
Apr 10, 2025
Initiates: Outperform
Price Target: $2
Current: $0.60
Upside: +233.33%
Tandem Diabetes Care
Apr 10, 2025
Initiates: Neutral
Price Target: $20
Current: $23.45
Upside: -14.71%
DexCom
Apr 10, 2025
Initiates: Outperform
Price Target: $85
Current: $85.05
Upside: -0.06%
Exact Sciences
Apr 10, 2025
Initiates: Outperform
Price Target: $60
Current: $53.40
Upside: +12.36%
Alcon
Mar 28, 2025
Maintains: Outperform
Price Target: $115 → $120
Current: $94.79
Upside: +26.60%
Tarsus Pharmaceuticals
Mar 6, 2025
Maintains: Buy
Price Target: $54 → $58
Current: $44.20
Upside: +31.22%
LivaNova
Feb 26, 2025
Maintains: Outperform
Price Target: $70 → $60
Current: $45.23
Upside: +32.66%
Nov 5, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $58.81
Upside: +47.93%
Nov 1, 2024
Maintains: Neutral
Price Target: $275 → $250
Current: $129.24
Upside: +93.44%
Oct 24, 2024
Maintains: Outperform
Price Target: $100 → $110
Current: $102.87
Upside: +6.93%
Oct 17, 2024
Maintains: Neutral
Price Target: $115 → $130
Current: $131.99
Upside: -1.51%
Jun 20, 2024
Maintains: Buy
Price Target: $12 → $14
Current: $20.45
Upside: -31.54%
Jun 6, 2024
Maintains: Buy
Price Target: $65 → $70
Current: $34.58
Upside: +102.43%
May 8, 2024
Maintains: Buy
Price Target: $53 → $55
Current: $20.27
Upside: +171.34%
May 3, 2024
Maintains: Buy
Price Target: $90 → $100
Current: $79.52
Upside: +25.75%
May 1, 2024
Maintains: Buy
Price Target: $110 → $105
Current: $74.11
Upside: +41.68%
Apr 11, 2024
Maintains: Buy
Price Target: $95 → $105
Current: $74.80
Upside: +40.37%
Mar 27, 2024
Maintains: Buy
Price Target: $215
Current: $247.66
Upside: -13.19%
Mar 27, 2024
Maintains: Buy
Price Target: $250
Current: $156.44
Upside: +59.81%
Mar 1, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $7.25
Upside: +93.10%
Mar 1, 2024
Maintains: Buy
Price Target: $103 → $115
Current: $84.45
Upside: +36.18%
Feb 21, 2024
Maintains: Buy
Price Target: $95 → $98
Current: $85.81
Upside: +14.21%
Jan 25, 2024
Maintains: Neutral
Price Target: $350 → $390
Current: $561.43
Upside: -30.53%
Aug 3, 2023
Downgrades: Hold
Price Target: $63 → $67
Current: $82.46
Upside: -18.75%
Feb 8, 2023
Maintains: Buy
Price Target: $110 → $115
Current: $70.26
Upside: +63.68%
Nov 5, 2021
Maintains: Buy
Price Target: $200 → $175
Current: $98.22
Upside: +78.17%
May 13, 2020
Maintains: Hold
Price Target: $30 → $25
Current: $7.52
Upside: +232.45%